#immunotherapy

Tests prevented relapse and limited graft-vs.-host disease (GVHD) in laboratory models of leukemia and multiple myeloma.

Many cancer patients eligible for CAR-T therapy must live away from home for several months while they complete treatment.

Can a person’s immune system help prevent two types of non-small-cell lung cancer? Here’s how Robert Keith, MD, hopes to find out.

A new report tracks the most prominent cancers for men and women and finds substantial racial disparities in cancer treatment.

Microorganisms in the gut influence how the body responds to common cancer treatments, including immunotherapy.

Compared with men, women had a 34% greater likelihood of adverse events, especially if they received immunotherapy.

New insights into why men fail to mount as powerful an immune response to many cancers as women do.

98% of people who received the customized immunotherapy responded to the one-time treatment.

Single-cell sequencing tech enables deep dive into mysterious results, sets stage for future improvements.

The largest peer-reviewed study of the Pfizer-BioNTech COVID vaccine in cancer patients finds no more, and no different, side effects.

Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.

The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.

Providers who treat smokers with lung cancer should offer support to help them quit.

Allergy meds were linked to longer survival among cancer patients treated with immune checkpoint inhibitors.

Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.

Low fiber consumption and use of probiotics were linked to poorer response to checkpoint inhibitors for melanoma patients.